Heron Therapeutics Stock Price, News & Analysis (NASDAQ:HRTX)

$15.50 -0.27 (-1.71 %)
(As of 12/13/2017 01:57 AM ET)
Previous Close$15.77
Today's Range$15.50 - $15.95
52-Week Range$12.21 - $18.40
Volume802,200 shs
Average Volume840,667 shs
Market Capitalization$1.02 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.13

About Heron Therapeutics (NASDAQ:HRTX)

Heron Therapeutics logoHeron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company's SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.

Receive HRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:HRTX
CUSIPN/A
Phone858-251-4400

Debt

Debt-to-Equity Ratio0.62%
Current Ratio2.12%
Quick Ratio2.02%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.28 million
Price / Sales777.18
Cash FlowN/A
Price / CashN/A
Book Value($0.41) per share
Price / Book-37.80

Profitability

Trailing EPS($3.79)
Net Income$-173,140,000.00
Net Margins-831.89%
Return on Equity-385.11%
Return on Assets-141.39%

Miscellaneous

Employees139
Outstanding Shares64,180,000

Heron Therapeutics (NASDAQ:HRTX) Frequently Asked Questions

What is Heron Therapeutics' stock symbol?

Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX."

How were Heron Therapeutics' earnings last quarter?

Heron Therapeutics Inc (NASDAQ:HRTX) issued its quarterly earnings results on Monday, November, 6th. The biotechnology company reported ($0.77) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.87) by $0.10. The biotechnology company earned $8.57 million during the quarter, compared to the consensus estimate of $8.12 million. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%. View Heron Therapeutics' Earnings History.

Where is Heron Therapeutics' stock going? Where will Heron Therapeutics' stock price be in 2017?

10 analysts have issued 1 year price objectives for Heron Therapeutics' stock. Their predictions range from $21.00 to $40.00. On average, they expect Heron Therapeutics' stock price to reach $29.80 in the next year. View Analyst Ratings for Heron Therapeutics.

What are Wall Street analysts saying about Heron Therapeutics stock?

Here are some recent quotes from research analysts about Heron Therapeutics stock:

  • 1. Mizuho analysts commented, "We analyze in greater detail Heron Therapeutics’ product HTX-011 to better understand the benefits of this extended-release combination of bupivacaine and anti-inflammatory agent meloxicam. Local anesthetics appear to lose efficacy when used in an acidic environment produced by inflammation whereas HTX-011 addresses the issue by the use of an anti-inflammation agent. We see significant upside potential if HTX-011 phase 3 readouts are positive. KeyPoints Inflammation is an unmet issue in local anesthetics. Local anesthetic failure has been observed when associated with inflammation. On page 2 and 3, we discuss two research publications to explain how inflammation can affect local anesthetics. Two theories are summarized by the authors providing evidence of reduced efficacy in generic bupivacaine when used by itself. Specifically, bupivacaine loses efficacy when used in an acidic environment produced by inflammation." (12/8/2017)
  • 2. According to Zacks Investment Research, "Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. " (11/22/2017)
  • 3. Cantor Fitzgerald analysts commented, "We hosted our annual Cantor Fitzgerald Healthcare Conference in New York today, with HRTX in attendance." (9/25/2017)
  • 4. Cowen Inc analysts commented, "Earlier today Heron stock dropped as much as 8.5% on seemingly no news." (5/26/2017)
  • 5. Needham & Company LLC analysts commented, "We initiate coverage of Heron Therapeutics, a commercial-stage specialty biopharma focused on novel extended-release injectables, at Buy with a $28 PT. HRTX made the transition to a commercial co. in 4Q16 with the launch of Sustol for CINV. Cinvanti, on file with FDA (likely 4Q17 PDUFA), will round out the CINV franchise. The main value driver, HTX-011, is an extended-release combination of bupivacaine/meloxicam in development for post-op pain management. HTX-011 successfully completed a comprehensive ph 2 program in various surgical procedures demonstrating superior efficacy to placebo and bupivacaine. HTX-011 will begin ph 3 development in 2017. Our valuation looks at the differentiated CINV assets and cash balance (~$215MM) as a floor value for HRTX, while the potential of HTX-011 remains mostly undervalued." (2/27/2017)

Who are some of Heron Therapeutics' key competitors?

Who are Heron Therapeutics' key executives?

Heron Therapeutics' management team includes the folowing people:

  • Kevin C. Tang, Independent Chairman of the Board (Age 50)
  • Robert Harvey Rosen, President, Director (Age 61)
  • Barry D. Quart Pharm.D., Chief Executive Officer, Director (Age 60)
  • Robert E. Hoffman, Chief Financial Officer, Senior Vice President - Finance (Age 51)
  • Kimberly J. Manhard, Executive Vice President - Drug Development
  • David L. Szekeres, Senior Vice President, General Counsel, Business Development, Corporate Secretary (Age 43)
  • Thomas B. Ottoboni Ph.D., Senior Vice President - Pharmaceutical and Preclinical Research and Development (Age 58)
  • Sean T. Ristine, Vice President - Human Resources (Age 47)
  • Christian Waage, Director (Age 50)
  • Craig A. Johnson, Independent Director (Age 56)

Who owns Heron Therapeutics stock?

Heron Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Janus Henderson Group PLC (10.58%), Rubric Capital Management LP (3.49%), Alyeska Investment Group L.P. (1.38%), Perceptive Advisors LLC (0.61%), Schwab Charles Investment Management Inc. (0.30%) and Chartwell Investment Partners LLC (0.27%). Company insiders that own Heron Therapeutics stock include Kevin C Tang, Kimberly Manhard and Robert Rosen. View Institutional Ownership Trends for Heron Therapeutics.

Who sold Heron Therapeutics stock? Who is selling Heron Therapeutics stock?

Heron Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C., Schwab Charles Investment Management Inc., California State Teachers Retirement System and Quantbot Technologies LP. View Insider Buying and Selling for Heron Therapeutics.

Who bought Heron Therapeutics stock? Who is buying Heron Therapeutics stock?

Heron Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Rubric Capital Management LP, Chartwell Investment Partners LLC, Janus Henderson Group PLC, Fisher Asset Management LLC, C WorldWide Group Holding A S, Wells Fargo & Company MN and Alyeska Investment Group L.P.. View Insider Buying and Selling for Heron Therapeutics.

How do I buy Heron Therapeutics stock?

Shares of Heron Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Heron Therapeutics' stock price today?

One share of Heron Therapeutics stock can currently be purchased for approximately $15.50.

How big of a company is Heron Therapeutics?

Heron Therapeutics has a market capitalization of $1.02 billion and generates $1.28 million in revenue each year. The biotechnology company earns $-173,140,000.00 in net income (profit) each year or ($3.79) on an earnings per share basis. Heron Therapeutics employs 139 workers across the globe.

How can I contact Heron Therapeutics?

Heron Therapeutics' mailing address is 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-251-4400 or via email at [email protected]


MarketBeat Community Rating for Heron Therapeutics (HRTX)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  343 (Vote Outperform)
Underperform Votes:  128 (Vote Underperform)
Total Votes:  471
MarketBeat's community ratings are surveys of what our community members think about Heron Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Heron Therapeutics (NASDAQ:HRTX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $32.00$32.00$35.11$36.33
Price Target Upside: 107.12% upside95.72% upside130.24% upside144.67% upside

Heron Therapeutics (NASDAQ:HRTX) Consensus Price Target History

Price Target History for Heron Therapeutics (NASDAQ:HRTX)

Heron Therapeutics (NASDAQ:HRTX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/8/2017MizuhoReiterated RatingBuy$28.00MediumView Rating Details
12/6/2017CowenReiterated RatingBuy$40.00MediumView Rating Details
11/12/2017Noble FinancialReiterated RatingBuyN/AView Rating Details
11/10/2017OppenheimerReiterated RatingBuy$27.00N/AView Rating Details
11/2/2017Cantor FitzgeraldReiterated RatingBuy$31.00N/AView Rating Details
9/27/2017Northland SecuritiesInitiated CoverageOutperform -> Outperform$40.00LowView Rating Details
8/16/2017Jefferies GroupReiterated RatingBuyLowView Rating Details
7/18/2017AegisReiterated RatingBuy$33.00LowView Rating Details
2/27/2017Needham & Company LLCInitiated CoverageBuy -> Buy$28.00N/AView Rating Details
1/5/2017Leerink SwannSet Price TargetBuy$21.00N/AView Rating Details
11/9/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$41.00N/AView Rating Details
9/6/2016Lake Street CapitalReiterated RatingBuy$45.00N/AView Rating Details
(Data available from 12/13/2015 forward)

Earnings

Heron Therapeutics (NASDAQ:HRTX) Earnings History and Estimates Chart

Earnings by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Heron Therapeutics (NASDAQ HRTX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017Q3 2017($0.87)($0.77)$8.12 million$8.57 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.90)($0.80)$4.53 million$8.51 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.94)($1.00)$1.96 million$3.63 millionViewN/AView Earnings Details
2/23/2017Q4 2016($1.17)($1.22)$1.07 million$1.28 millionViewN/AView Earnings Details
11/8/2016Q3 2016($1.17)($1.24)ViewN/AView Earnings Details
8/8/2016Q2($0.96)($1.17)ViewN/AView Earnings Details
5/5/2016Q1($0.92)($0.92)ViewN/AView Earnings Details
2/19/2016Q4($0.64)($0.87)ViewN/AView Earnings Details
11/6/2015Q3($0.67)($0.63)ViewN/AView Earnings Details
8/7/2015Q2 2015($0.65)($0.74)ViewN/AView Earnings Details
5/8/2015Q115($0.64)($0.70)ViewN/AView Earnings Details
3/13/2015Q4 2014($0.69)($0.71)ViewN/AView Earnings Details
11/6/2014Q3 2014($0.69)($0.66)ViewN/AView Earnings Details
8/4/2014Q2 2014($0.62)($0.78)ViewN/AView Earnings Details
5/8/2014Q1 2014($0.58)($0.74)ViewN/AView Earnings Details
3/5/2014($0.53)($0.75)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Heron Therapeutics (NASDAQ:HRTX) Earnings Estimates

2017 EPS Consensus Estimate: ($3.57)
2018 EPS Consensus Estimate: ($2.83)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.86)($0.86)($0.86)
Q2 20172($1.04)($0.99)($1.02)
Q3 20173($0.89)($0.80)($0.84)
Q4 20173($0.96)($0.72)($0.85)
Q1 20181($0.87)($0.87)($0.87)
Q2 20181($0.81)($0.81)($0.81)
Q3 20181($0.66)($0.66)($0.66)
Q4 20181($0.49)($0.49)($0.49)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Heron Therapeutics (NASDAQ:HRTX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Heron Therapeutics (NASDAQ HRTX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 19.93%
Insider Trades by Quarter for Heron Therapeutics (NASDAQ:HRTX)
Insider Trades by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Heron Therapeutics (NASDAQ HRTX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/24/2017Kimberly ManhardVPSell21,542$15.33$330,238.86View SEC Filing  
1/19/2017Kevin C TangDirectorBuy2,459,016$12.20$29,999,995.20View SEC Filing  
8/10/2016Robert RosenInsiderSell100,000$23.30$2,330,000.00View SEC Filing  
4/21/2016Robert RosenPresidentSell200,000$23.23$4,646,000.00View SEC Filing  
6/10/2015Kevin C TangDirectorBuy121,212$24.75$2,999,997.00View SEC Filing  
6/2/2015Kevin C TangDirectorBuy150,000$20.62$3,093,000.00View SEC Filing  
6/1/2015Kimberly ManhardDirectorSell2,708$21.17$57,328.36View SEC Filing  
6/25/2014Barry D QuartCEOBuy10,000$11.75$117,500.00View SEC Filing  
6/25/2014Kevin C TangDirectorBuy510,638$11.75$5,999,996.50View SEC Filing  
11/20/2013Barry D QuartCEOBuy1,000,000$0.40$400,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Heron Therapeutics (NASDAQ HRTX) News Headlines

Source:
DateHeadline
Heron Therapeutics (HRTX) "Buy" Rating Reiterated at MizuhoHeron Therapeutics' (HRTX) "Buy" Rating Reiterated at Mizuho
www.americanbankingnews.com - December 9 at 12:08 PM
Investors Purchase High Volume of Call Options on Heron Therapeutics (HRTX)Investors Purchase High Volume of Call Options on Heron Therapeutics (HRTX)
www.americanbankingnews.com - December 8 at 1:32 AM
Cowen Reiterates "Buy" Rating for Heron Therapeutics (HRTX)Cowen Reiterates "Buy" Rating for Heron Therapeutics (HRTX)
www.americanbankingnews.com - December 7 at 3:38 PM
Heron Therapeutics To Take Flight In 2018 - Seeking AlphaHeron Therapeutics To Take Flight In 2018 - Seeking Alpha
seekingalpha.com - December 6 at 8:13 AM
Heron Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HRTX-US : December 6, 2017Heron Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HRTX-US : December 6, 2017
finance.yahoo.com - December 6 at 8:13 AM
Why Heron Therapeutics Stock Is Crashing TodayWhy Heron Therapeutics Stock Is Crashing Today
finance.yahoo.com - December 6 at 8:13 AM
After-Hours Stock Movers 12/04: (COLL) (DEPO) Higher; (ASNA) (HRTX) (HOME) Lower (more...)After-Hours Stock Movers 12/04: (COLL) (DEPO) Higher; (ASNA) (HRTX) (HOME) Lower (more...)
www.streetinsider.com - December 5 at 3:24 PM
GALT Faces Big Test Today, ABBV Clears Psoriasis Trial, DEPO Cuts 40% Of Staff - NasdaqGALT Faces Big Test Today, ABBV Clears Psoriasis Trial, DEPO Cuts 40% Of Staff - Nasdaq
www.nasdaq.com - December 5 at 7:49 AM
Heron Therapeutics (HRTX) Plans Public Offering of Common Stock - StreetInsider.comHeron Therapeutics (HRTX) Plans Public Offering of Common Stock - StreetInsider.com
www.streetinsider.com - December 5 at 7:49 AM
Heron Therapeutics Announces Public Offering of Common StockHeron Therapeutics Announces Public Offering of Common Stock
finance.yahoo.com - December 5 at 7:49 AM
Free Research Reports on These Drug Makers Stocks -- Novartis, Heron Therapeutics, Aerie Pharma, and PfizerFree Research Reports on These Drug Makers Stocks -- Novartis, Heron Therapeutics, Aerie Pharma, and Pfizer
www.bizjournals.com - December 1 at 8:39 AM
Heron Therapeutics (HRTX) Upgraded to "Hold" by ValuEngineHeron Therapeutics (HRTX) Upgraded to "Hold" by ValuEngine
www.americanbankingnews.com - November 30 at 10:28 PM
Heron Therapeutics, Inc. (HRTX) Given Consensus Recommendation of "Buy" by AnalystsHeron Therapeutics, Inc. (HRTX) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - November 30 at 7:46 PM
$7.98 Million in Sales Expected for Heron Therapeutics, Inc. (HRTX) This Quarter$7.98 Million in Sales Expected for Heron Therapeutics, Inc. (HRTX) This Quarter
www.americanbankingnews.com - November 30 at 4:34 PM
 Brokerages Expect Heron Therapeutics, Inc. (HRTX) to Announce -$0.83 EPS Brokerages Expect Heron Therapeutics, Inc. (HRTX) to Announce -$0.83 EPS
www.americanbankingnews.com - November 28 at 3:27 AM
What does Heron Therapeutics Incs (HRTX) Balance Sheet Tell Us Abouts Its Future? - Yahoo FinanceWhat does Heron Therapeutics Inc's (HRTX) Balance Sheet Tell Us Abouts Its Future? - Yahoo Finance
finance.yahoo.com - November 23 at 4:49 PM
Heron Therapeutics, Inc. (HRTX) Lifted to Buy at Zacks Investment ResearchHeron Therapeutics, Inc. (HRTX) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - November 23 at 12:46 AM
What does Heron Therapeutics Inc’s (HRTX) Balance Sheet Tell Us Abouts Its Future?What does Heron Therapeutics Inc’s (HRTX) Balance Sheet Tell Us Abouts Its Future?
finance.yahoo.com - November 21 at 7:39 PM
Heron Therapeutics: Wait For A Dip Before Jumping In - Seeking AlphaHeron Therapeutics: Wait For A Dip Before Jumping In - Seeking Alpha
seekingalpha.com - November 18 at 6:44 PM
Heron Therapeutics (HRTX) Presents At Jefferies 2017 London Healthcare Conference - SlideshowHeron Therapeutics (HRTX) Presents At Jefferies 2017 London Healthcare Conference - Slideshow
seekingalpha.com - November 17 at 2:18 PM
Heron Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : HRTX-US : November 17, 2017Heron Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : HRTX-US : November 17, 2017
finance.yahoo.com - November 17 at 2:18 PM
Heron Therapeutics Looks To Take Mercks CINV Market Share - Seeking AlphaHeron Therapeutics Looks To Take Merck's CINV Market Share - Seeking Alpha
seekingalpha.com - November 14 at 8:04 PM
FY2020 Earnings Forecast for Heron Therapeutics, Inc. (HRTX) Issued By Oppenheimer HoldingsFY2020 Earnings Forecast for Heron Therapeutics, Inc. (HRTX) Issued By Oppenheimer Holdings
www.americanbankingnews.com - November 13 at 10:30 AM
Heron Therapeutics (HRTX) Announces U.S. FDA Approval of CINVANTI(TM) - SlideshowHeron Therapeutics (HRTX) Announces U.S. FDA Approval of CINVANTI(TM) - Slideshow
seekingalpha.com - November 12 at 8:00 PM
Noble Financial Reaffirms "Buy" Rating for Heron Therapeutics, Inc. (HRTX)Noble Financial Reaffirms "Buy" Rating for Heron Therapeutics, Inc. (HRTX)
www.americanbankingnews.com - November 12 at 3:50 PM
Heron Therapeutics (HRTX): Second Product To Leverage Existing Sales Force - Cowen - StreetInsider.comHeron Therapeutics (HRTX): Second Product To Leverage Existing Sales Force - Cowen - StreetInsider.com
www.streetinsider.com - November 12 at 10:24 AM
Heron Therapeutics (HRTX) Announces U.S. FDA Approval of CINVANTI for Prevention of CINVHeron Therapeutics (HRTX) Announces U.S. FDA Approval of CINVANTI for Prevention of CINV
www.streetinsider.com - November 11 at 9:50 AM
Heron Therapeutics Announces U.S. FDA Approval of CINVANTI™ (aprepitant) Injectable Emulsion for the Prevention of Acute and Delayed Chemotherapy-Induced Nausea and Vomiting (CINV)Heron Therapeutics Announces U.S. FDA Approval of CINVANTI™ (aprepitant) Injectable Emulsion for the Prevention of Acute and Delayed Chemotherapy-Induced Nausea and Vomiting (CINV)
finance.yahoo.com - November 11 at 9:50 AM
Zacks: Brokerages Expect Heron Therapeutics, Inc. (HRTX) Will Post Quarterly Sales of $7.22 MillionZacks: Brokerages Expect Heron Therapeutics, Inc. (HRTX) Will Post Quarterly Sales of $7.22 Million
www.americanbankingnews.com - November 11 at 6:40 AM
Heron Therapeutics, Inc. (HRTX) Earns "Buy" Rating from Oppenheimer Holdings, Inc.Heron Therapeutics, Inc. (HRTX) Earns "Buy" Rating from Oppenheimer Holdings, Inc.
www.americanbankingnews.com - November 10 at 1:44 PM
FY2017 EPS Estimates for Heron Therapeutics, Inc. (HRTX) Raised by AnalystFY2017 EPS Estimates for Heron Therapeutics, Inc. (HRTX) Raised by Analyst
www.americanbankingnews.com - November 10 at 7:40 AM
-$0.89 EPS Expected for Heron Therapeutics, Inc. (HRTX) This Quarter-$0.89 EPS Expected for Heron Therapeutics, Inc. (HRTX) This Quarter
www.americanbankingnews.com - November 9 at 1:44 PM
Heron Therapeutics, Inc. (HRTX) Upgraded to "Hold" by Zacks Investment ResearchHeron Therapeutics, Inc. (HRTX) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - November 9 at 12:26 AM
Heron Therapeutics to Present at the Jefferies London Healthcare ConferenceHeron Therapeutics to Present at the Jefferies London Healthcare Conference
finance.yahoo.com - November 8 at 8:29 PM
Heron Therapeutics, Inc. – Value Analysis (NASDAQ:HRTX) : November 7, 2017Heron Therapeutics, Inc. – Value Analysis (NASDAQ:HRTX) : November 7, 2017
finance.yahoo.com - November 8 at 9:49 AM
Heron Therapeutics, Inc. (HRTX) Announces Quarterly  Earnings Results, Beats Estimates By $0.10 EPSHeron Therapeutics, Inc. (HRTX) Announces Quarterly Earnings Results, Beats Estimates By $0.10 EPS
www.americanbankingnews.com - November 7 at 2:22 PM
What Is Heron Therapeutics Inc’s (HRTX) Share Price Doing?What Is Heron Therapeutics Inc’s (HRTX) Share Price Doing?
finance.yahoo.com - November 7 at 2:40 AM
Heron Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : HRTX-US : November 6, 2017Heron Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : HRTX-US : November 6, 2017
finance.yahoo.com - November 7 at 2:40 AM
The Zacks Analyst Blog Highlights: Keryx Biopharmaceuticals, Bristol-Myers Squibb, Dynavax Technologies, Heron Therapeutics and Ultragenyx PharmaceuticalThe Zacks Analyst Blog Highlights: Keryx Biopharmaceuticals, Bristol-Myers Squibb, Dynavax Technologies, Heron Therapeutics and Ultragenyx Pharmaceutical
finance.yahoo.com - November 7 at 2:40 AM
Heron Therapeutics Reports Financial Results for the Three and Nine Months Ended September 30, 2017 and Recent Corporate ProgressHeron Therapeutics Reports Financial Results for the Three and Nine Months Ended September 30, 2017 and Recent Corporate Progress
finance.yahoo.com - November 7 at 2:40 AM
Heron Therapeutics reports 3Q lossHeron Therapeutics reports 3Q loss
finance.yahoo.com - November 7 at 2:40 AM
Heron Therapeutics, Inc. (HRTX) Given "Buy" Rating at Cowen and CompanyHeron Therapeutics, Inc. (HRTX) Given "Buy" Rating at Cowen and Company
www.americanbankingnews.com - November 6 at 11:36 PM
Heron Therapeutics, Inc. (HRTX) Receives Consensus Recommendation of "Buy" from BrokeragesHeron Therapeutics, Inc. (HRTX) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - November 5 at 5:38 PM
Analyzing Heron Therapeutics (HRTX) & Zynerba Pharmaceuticals (ZYNE)Analyzing Heron Therapeutics (HRTX) & Zynerba Pharmaceuticals (ZYNE)
www.americanbankingnews.com - November 3 at 7:10 PM
Analysts Issue Forecasts for Heron Therapeutics, Inc.s Q3 2017 Earnings (HRTX)Analysts Issue Forecasts for Heron Therapeutics, Inc.'s Q3 2017 Earnings (HRTX)
www.americanbankingnews.com - November 2 at 6:22 AM
Heron Therapeutics, Inc. (HRTX) Earns Buy Rating from Analysts at Oppenheimer Holdings Inc.Heron Therapeutics, Inc. (HRTX) Earns Buy Rating from Analysts at Oppenheimer Holdings Inc.
www.americanbankingnews.com - October 30 at 6:34 PM
Heron Therapeutics, Inc. (HRTX) Scheduled to Post Quarterly Earnings on MondayHeron Therapeutics, Inc. (HRTX) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - October 30 at 1:50 PM
Heron Therapeutics (HRTX) Granted FDA Fast Track Designation for HTX-011 to Reduce Postoperative PainHeron Therapeutics (HRTX) Granted FDA Fast Track Designation for HTX-011 to Reduce Postoperative Pain
www.streetinsider.com - October 28 at 8:02 PM
Short Interest in Heron Therapeutics, Inc. (HRTX) Drops By 11.2%Short Interest in Heron Therapeutics, Inc. (HRTX) Drops By 11.2%
www.americanbankingnews.com - October 27 at 1:40 AM
Heron Therapeutics (HRTX) Granted FDA Fast Track Designation for HTX-011 to Reduce Postoperative Pain - StreetInsider.comHeron Therapeutics (HRTX) Granted FDA Fast Track Designation for HTX-011 to Reduce Postoperative Pain - StreetInsider.com
www.streetinsider.com - October 26 at 11:42 AM

SEC Filings

Heron Therapeutics (NASDAQ:HRTX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Heron Therapeutics (NASDAQ:HRTX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Heron Therapeutics (NASDAQ HRTX) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.